UA111474C2 - Nanoparticles comprising metallic material covered with hafnium oxide material for producing therapeutic anticancer agent - Google Patents

Nanoparticles comprising metallic material covered with hafnium oxide material for producing therapeutic anticancer agent

Info

Publication number
UA111474C2
UA111474C2 UAA201408006A UAA201408006A UA111474C2 UA 111474 C2 UA111474 C2 UA 111474C2 UA A201408006 A UAA201408006 A UA A201408006A UA A201408006 A UAA201408006 A UA A201408006A UA 111474 C2 UA111474 C2 UA 111474C2
Authority
UA
Ukraine
Prior art keywords
nanoparticles
hafnium oxide
anticancer agent
metallic material
oxide material
Prior art date
Application number
UAA201408006A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Agnes Pottier
Laurent Levy
Marie-Edith Meyre
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Priority claimed from PCT/EP2012/075731 external-priority patent/WO2013087920A1/en
Publication of UA111474C2 publication Critical patent/UA111474C2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.
UAA201408006A 2011-12-16 2012-12-17 Nanoparticles comprising metallic material covered with hafnium oxide material for producing therapeutic anticancer agent UA111474C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576437P 2011-12-16 2011-12-16
PCT/EP2012/075731 WO2013087920A1 (en) 2011-12-16 2012-12-17 Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof

Publications (1)

Publication Number Publication Date
UA111474C2 true UA111474C2 (en) 2016-05-10

Family

ID=57142377

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201408006A UA111474C2 (en) 2011-12-16 2012-12-17 Nanoparticles comprising metallic material covered with hafnium oxide material for producing therapeutic anticancer agent

Country Status (1)

Country Link
UA (1) UA111474C2 (en)

Similar Documents

Publication Publication Date Title
MX362089B (en) Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof.
IL272313A (en) Intravascular delivery of nanoparticle compositions and uses thereof
MX2019000225A (en) Compositions and methods for treatment of autoimmune and other disease.
CA2863681A1 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
MX2020010535A (en) Methods of treating cancer.
HK1216880A1 (en) Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012177757A3 (en) Personal care compositions comprising shaped abrasive particles
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX2013003162A (en) Pharmaceutical composition.
MX343687B (en) Tricyclic sulfonamide compounds and methods of making and using same.
IN2015DN00392A (en)
UA109464C2 (en) Spiro-oxindoles as mdm2 antagonists
HK1178074A1 (en) Compositions and methods for the diagnosis and treatment of tumor
PT2555763E (en) Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-)-carvone, (+)-carvone, geraniol and a further essential oil component
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
WO2012121528A3 (en) Magnetic nanocomposite specific for thyroid cancer and use thereof
MX2014008705A (en) Tricyclic sulfone compounds and methods of making and using same.
MX2014008706A (en) Tricyclic sulfonamide compounds and methods of making and using same.
MX2015009348A (en) Hemostatic compositions.
WO2012012311A3 (en) Compositions and methods for synthesis of organic-silica hybrid materials
SA515360432B1 (en) Enemas
TN2013000379A1 (en) Fe(iii) complexes for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anaemias
UA111474C2 (en) Nanoparticles comprising metallic material covered with hafnium oxide material for producing therapeutic anticancer agent